Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Form: Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Reference Brands: Coly-Mycin M(US)

Category: Antibiotics

Colistin (Polymyxin E) inhalation solution is approved in the EU and US for treating Pseudomonas aeruginosa lung infections in cystic fibrosis patients. In Europe, brands like Colobreathe are regulated by EMA, supported by dossiers on safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data, with generic options available. Both regions require detailed dossiers, including clinical trial results, quality practices, and pharmacovigilance plans for approval and safety monitoring. Due to its specialized pulmonary use, strict regulations on dosing, storage, and safety follow. For expert regulatory support and seamless market entry, visit PharmaTradz. We ensure compliance with European and US standards for safe, effective inhalation therapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Fosfomycin Oral Sachets or Powder for Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details Get Enquiry
Fosfomycin IV

Strength: 2 g, 4g per vial

Form: Intravenous (IV)

Reference Brands: Zyflo(US)

View Details Get Enquiry
Teicoplanin Injectable (IV/IM)

Strength: 200 mg/100 mL, 400 mg/200 mL, 400 mg/100 mL

Form: Injectable (IV/IM)

Reference Brands: Targocid, Tolocin(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.